Biogen, Stakeholders, Advocacy Group React to CMS Aduhelm Coverage Decision

Could Biogen sidestep the Centers for Medicare and Medicaid Services (CMS) coverage decision that threatens to topple its longed-for Alzheimer’s treatment franchise?
Source: Drug Industry Daily